Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
the only primary-source injectable figure is an animal / formulation intradermal range of 100500 mcg per 0.1 mL from a 1990s hair-growth patent [4]
Early studies on 5-Amino-1MQ show promising results, particularly in animal models
Not for human use
US$ 24.15
US$ 26.23
US$ 21.25
/https://s3-images.chiaki.vn/seller/1766688680422/cloud-image-1766688680422-z7365778225228_cdc161229bf6e37f8d0c8aa83ff24e22.jpg)
US$ 22.92
